APR 1 6 2002

AP

●RECEIVED

APR 1 8 2002

TECH CENTER 160072900ENT

10/B

TECH CENTER 1000/230

Atty. Docket No.:

DX0725K2B

CN 028008

deposited with the United States Postal Service in an envelope addressed to:
BOX SEQUENCE, ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, D.C. 20231,

☑ under 37CFR § 1.8(a), with sufficient postage as first class mail, or
☐ under 37CFR § 1.10, as "Express Mail Post Office to Addressee" Mailing Label

No. _____, transmitted by facsimile to the Patent and Trademark Office, Fax Number

(703) 308-4242 , Attention: Examiner Kemmerer, ART UNIT 1646.

Date: April 8, 2002 By:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hedrick, et al.

Serial No.:

09/770,528

Filed:

January 25, 2001

For:

Mammalian Cytokines; Related

Reagents and Methods

Examiner: Elizabeth Kemmerer

Art Unit:

1646

RESPONSE TO NOTICE TO COMPLY
AND AMENDMENT
UNDER 37 C.F.R. 1.115

Palo Alto, California 94304

BOX SEQUENCE Assistant Commissioner for Patents Washington, D.C. 20231

Honorable Sir:

In response to the "Notice to Comply" with sequence listing requirements mailed March 6, 2002, Applicants submit the following amendment and response.

IN THE SPECIFICATION:

Please replace the paragraph starting on page 6, lines 4-37, and continuing to page 7, lines 1-15, with the following replacement paragraph:

--Certain polypeptide embodiments include an isolated or recombinant polypeptide that: A) specifically binds polyclonal antibodies generated against a 12 consecutive amino acid segment of SEQ ID NO: 2; and comprises at least one